Genetic mouse models for bone studies-Strengths and limitations

Bone

Volumn 49, Issue 6, 2011, Pages 1242-1254

  Elefteriou, Florent ^a   Yang, Xiangli ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone promoters; Conditional knock out; Cre recombinase; Cre lox system; Gene deletion; Knock in; Knock out; Mouse model; Transgenic

Indexed keywords

AGGRECAN; CATHEPSIN K; CD11B ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 10; COLLAGEN TYPE 2; CRE RECOMBINASE; DOXYCYCLINE; GANCICLOVIR; LYSOZYME; MIFEPRISTONE; NEOMYCIN; PROGESTERONE; TAMOXIFEN; TETRACYCLINE; THYMIDINE KINASE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR TWIST; ZINC FINGER PROTEIN;

AGGRECAN GENE; ANIMAL GENETICS; BONE EXAMINATION; CD11B GENE; CELL SELECTION; CHIMERA; CHROMOSOME REARRANGEMENT; COL1 ALPHA1 GENE; COL10 ALPHA1 GENE; COL2 ALPHA1 GENE; CTSK GENE; DERMO1 GENE; DNA POLYMORPHISM; DNA RECOMBINATION; DNA SEQUENCE; ENZYME ACTIVITY; GENE; GENE ACTIVITY; GENE DELETION; GENE DOSAGE; GENE FUNCTION; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC ANALYSIS; GENETIC MODEL; IN VITRO STUDY; IN VIVO STUDY; INTEGRATION; LIGAND BINDING; M LYSOZYME GENE; MOLECULAR CLONING; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTERIX GENE; PHENOTYPE; PRACTICE GUIDELINE; PROCESS DEVELOPMENT; PROCESS MODEL; PROMOTER REGION; PROTEIN DOMAIN; PRX1 GENE; REVIEW; RUNX2 GENE; SOX9 GENE; TRANSGENE; TRANSGENIC MOUSE; TRANSGENICS; TRAP GENE; WILD TYPE;

ANIMALS; BONE AND BONES; GENE DELETION; GENE TARGETING; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; PROMOTER REGIONS, GENETIC; TRANSGENES;

EID: 81355160516     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.08.021     Document Type: Review

References (107)

1. Goren I., Allmann N., Yogev N., Schurmann C., Linke A., Holdener M., et al. A transgenic mouse model of inducible macrophage depletion: effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. Am J Pathol 2009, 175:132-147.
2. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007, 5:464-475.
3. Roebroek A.J., Wu X., Bram R.J. Knockin Approaches 2002, 187-200.
4. Urnov F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010, 11:636-646.
5. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis 2000, 26:99-109.
6. Soriano P. Generalized lacZ expression ith the ROSA26 Cre reporter strain. Nat Genet 1999, 14:670-689.
7. Akiyama H., Kim J.E., Nakashima K., Balmes G., Iwai N., Deng J.M., et al. Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. Proc Natl Acad Sci USA 2005, 102:14665-14670.
8. Brocard J., Warot X., Wendling O., Messaddeq N., Vonesch J.L., Chambon P., et al. Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc Natl Acad Sci USA 1997, 94:14559-14563.
9. Metzger D., Chambon P. Site- and time-specific gene targeting in the mouse. Methods 2001, 24:71-80.
10. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992, 89:5547-5551.
11. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995, 268:1766-1769.
12. Indra A.K., Warot X., Brocard J., Bornert J.M., Xiao J.H., Chambon P., et al. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 1999, 27:4324-4327.
13. Kim J.E., Nakashima K., de Crombrugghe B. Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth. Am J Pathol 2004, 165:1875-1882.
14. Zhu M., Chen M., Lichtler A.C., O'Keefe R.J., Chen D. Tamoxifen-inducible Cre-recombination in articular chondrocytes of adult Col2a1-CreER(T2) transgenic mice. Osteoarthritis Cartilage 2008, 16:129-130.
15. Kistner A., Gossen M., Zimmermann F., Jerecic J., Ullmer C., Lubbert H., et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 1996, 93:10933-10938.
16. Horton W.A. Skeletal development: insights from targeting the mouse genome. Lancet 2003, 362:560-569.
17. Karsenty G., Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002, 2:389-406.
18. Logan M., Martin J.F., Nagy A., Lobe C., Olson E.N., Tabin C.J. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 2002, 33:77-80.
19. Kolanczyk M., Kossler N., Kuhnisch J., Lavitas L., Stricker S., Wilkening U., et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 2007, 16:874-886.
20. Yu K., Xu J., Liu Z., Sosic D., Shao J., Olson E.N., et al. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 2003, 130:3063-3074.
21. Liu Y., Wang L., Fatahi R., Kronenberg M., Kalajzic I., Rowe D., et al. Isolation of murine bone marrow derived mesenchymal stem cells using Twist2 Cre transgenic mice. Bone 2010, 47:916-925.
22. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739-750.
23. Horiuchi K., Kimura T., Miyamoto T., Miyamoto K., Akiyama H., Takaishi H., et al. Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis and increased granulopoiesis via dysregulation of IL-17 and G-CSF. J Immunol 2009, 182:2093-2101.
24. Haigh J.J., Gerber H.P., Ferrara N., Wagner E.F. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 2000, 127:1445-1453.
25. Karreth F., Hoebertz A., Scheuch H., Eferl R., Wagner E.F. The AP1 transcription factor Fra2 is required for efficient cartilage development. Development 2004, 131:5717-5725.
26. Downey C.M., Horton C.R., Carlson B.A., Parsons T.E., Hatfield D.L., Hallgrimsson B., et al. Osteo-chondroprogenitor-specific deletion of the selenocysteine tRNA gene, Trsp, leads to chondronecrosis and abnormal skeletal development: a putative model for Kashin-Beck disease. PLoS Genet 2009, 5:e1000616.
27. Ford-Hutchinson A.F., Ali Z., Lines S.E., Hallgrimsson B., Boyd S.K., Jirik F.R. Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth. J Bone Miner Res 2007, 22:1245-1259.
28. Hsieh S.C., Chen N.T., Lo S.H. Conditional loss of PTEN leads to skeletal abnormalities and lipoma formation. Mol Carcinog 2009, 48:545-552.
29. Wang W., Nyman J.S., Ono K., Stevenson D.A., Yang X., Elefteriou F. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet 2011, [Electronic publication ahead of print].
30. Ovchinnikov D.A., Deng J.M., Ogunrinu G., Behringer R.R. Col2a1-directed expression of Cre recombinase in differentiating chondrocytes in transgenic mice. Genesis 2000, 26:145-146.
31. Nakamura E., Nguyen M.T., Mackem S. Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreER(T) to assay temporal activity windows along the proximodistal limb skeleton. Dev Dyn 2006, 235:2603-2612.
32. Chen M., Lichtler A.C., Sheu T.J., Xie C., Zhang X., O'Keefe R.J., et al. Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. Genesis 2007, 45:44-50.
33. Hilton M.J., Tu X., Long F. Tamoxifen-inducible gene deletion reveals a distinct cell type associated with trabecular bone, and direct regulation of PTHrP expression and chondrocyte morphology by Ihh in growth region cartilage. Dev Biol 2007, 308:93-105.
34. Jones K.B., Piombo V., Searby C., Kurriger G., Yang B., Grabellus F., et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci USA 2010, 107:2054-2059.
35. Grover J., Roughley P.J. Generation of a transgenic mouse in which Cre recombinase is expressed under control of the type II collagen promoter and doxycycline administration. Matrix Biol 2006, 25:158-165.
36. Gebhard S., Hattori T., Bauer E., Schlund B., Bosl M.R., de Crombrugghe B., et al. Specific expression of Cre recombinase in hypertrophic cartilage under the control of a BAC-Col10a1 promoter. Matrix Biol 2008, 27:693-699.
37. Yang G., Cui F., Hou N., Cheng X., Zhang J., Wang Y., et al. Transgenic mice that express Cre recombinase in hypertrophic chondrocytes. Genesis 2005, 42:33-36.
38. Henry S.P., Jang C.W., Deng J.M., Zhang Z., Behringer R.R., de Crombrugghe B. Generation of aggrecan-CreERT2 knockin mice for inducible Cre activity in adult cartilage. Genesis 2009, 47:805-814.
39. Maes C., Goossens S., Bartunkova S., Drogat B., Coenegrachts L., Stockmans I., et al. Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J 2010, 29:424-441.
40. Rauch A., Seitz S., Baschant U., Schilling A.F., Illing A., Stride B., et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010, 11:517-531.
41. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., Roth S.I., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008, 22:1662-1676.
42. Provot S., Nachtrab G., Paruch J., Chen A.P., Silva A., Kronenberg H.M. A-raf and B-raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol Cell Biol 2008, 28:344-357.
43. Zhu W., Liang G., Huang Z., Doty S.B., Boskey A.L. Conditional inactivation of the CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to impaired osteoblast development. J Biol Chem 2011, 286:26794-26805.
44. Rodda S.J., McMahon A.P. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 2006, 133:3231-3244.
45. Maes C., Kobayashi T., Selig M.K., Torrekens S., Roth S.I., Mackem S., et al. Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels. Dev Cell 2010, 19:329-344.
46. Dacquin R., Starbuck M., Schinke T., Karsenty G. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn 2002, 224:245-251.
47. Hinoi E., Gao N., Jung D.Y., Yadav V., Yoshizawa T., Myers M.G., et al. The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 2008, 183:1235-1242.
48. Haberland M., Mokalled M.H., Montgomery R.L., Olson E.N. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009, 23:1625-1630.
49. Kato M., Patel M.S., Levasseur R., Lobov I., Chang B.H., Glass D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 2002, 157:303-314.
50. Elefteriou F., Benson M.D., Sowa H., Starbuck M., Liu X., Ron D., et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 2006, 4:441-451.
51. Baek W.Y., de Crombrugghe B., Kim J.E. Postnatally induced inactivation of Osterix in osteoblasts results in the reduction of bone formation and maintenance. Bone 2010, 46(4):920-928.
52. Liu F., Woitge H.W., Braut A., Kronenberg M.S., Lichtler A.C., Mina M., et al. Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol 2004, 48:645-653.
53. Gutierrez G.M., Kong E., Sabbagh Y., Brown N.E., Lee J.S., Demay M.B., et al. Impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice. Proc Natl Acad Sci USA 2008, 105:18402-18407.
54. Zhang M., Xuan S., Bouxsein M.L., von Stechow D., Akeno N., Faugere M.C., et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002, 277:44005-44012.
55. Zanotti S., Smerdel-Ramoya A., Stadmeyer L., Durant D., Radtke F., Canalis E. Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 2008, 149:3890-3899.
56. Yeo H., Beck L.H., Thompson S.R., Farach-Carson M.C., McDonald J.M., Clemens T.L., et al. Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption. J Biol Chem 2007, 282:35318-35327.
57. Tan X., Weng T., Zhang J., Wang J., Li W., Wan H., et al. Smad4 is required for maintaining normal murine postnatal bone homeostasis. J Cell Sci 2007, 120:2162-2170.
58. Liu X., Bruxvoort K.J., Zylstra C.R., Liu J., Cichowski R., Faugere M.C., et al. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 2007, 104:2259-2264.
59. Xiao Z., Dallas M., Qiu N., Nicolella D., Cao L., Johnson M., et al. Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J 2011, 25:2418-2432.
60. Lu Y., Xie Y., Zhang S., Dusevich V., Bonewald L.F., Feng J.Q. DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res 2007, 86:320-325.
61. Powell W.F., Barry K.J., Tulum I., Kobayashi T., Harris S.E., Bringhurst F.R., et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol 2011, 209:21-32.
62. Chiu W.S., McManus J.F., Notini A.J., Cassady A.I., Zajac J.D., Davey R.A. Transgenic mice that express Cre recombinase in osteoclasts. Genesis 2004, 39:178-185.
63. Dossa T., Arabian A., Windle J.J., Dedhar S., Teitelbaum S.L., Ross F.P., et al. Osteoclast-specific inactivation of the integrin-linked kinase (ILK) inhibits bone resorption. J Cell Biochem 2010, 110:960-967.
64. Kim H.J., Zhao H., Kitaura H., Bhattacharyya S., Brewer J.A., Muglia L.J., et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006, 116:2152-2160.
65. Martin-Millan M., Almeida M., Ambrogini E., Han L., Zhao H., Weinstein R.S., Jilka R.L., O'Brien C.A., Manolagas S.C. The Estrogen Receptor-{alpha} in Osteoclasts Mediates the Protective Effects of Estrogens on Cancellous But Not Cortical Bone. Mol Endocrinol 2010, 24:323-334.
66. Kenner L., Hoebertz A., Beil T., Keon N., Karreth F., Eferl R., et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol 2004, 164:613-623.
67. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999, 8:265-277.
68. Iwasawa M., Miyazaki T., Nagase Y., Akiyama T., Kadono Y., Nakamura M., et al. The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice. J Clin Invest 2009, 119:3149-3159.
69. Mizoguchi F., Izu Y., Hayata T., Hemmi H., Nakashima K., Nakamura T., et al. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J Cell Biochem 2009, 109(5):866-875.
70. Nakamura T., Imai Y., Matsumoto T., Sato S., Takeuchi K., Igarashi K., et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007, 130:811-823.
71. Ferron M., Vacher J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. Genesis 2005, 41:138-145.
72. Ishii M., Egen J.G., Klauschen F., Meier-Schellersheim M., Saeki Y., Vacher J., et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 2009, 458:524-528.
73. Otero J.E., Dai S., Foglia D., Alhawagri M., Vacher J., Pasparakis M., et al. Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem 2008, 283:24546-24553.
74. Lu M.F., Cheng H.T., Lacy A.R., Kern M.J., Argao E.A., Potter S.S., et al. Paired-related homeobox genes cooperate in handplate and hindlimb zeugopod morphogenesis. Dev Biol 1999, 205:145-157.
75. Martin J.F., Olson E.N. Identification of a prx1 limb enhancer. Genesis 2000, 26:225-229.
76. Kawanami A., Matsushita T., Chan Y.Y., Murakami S. Mice expressing GFP and CreER in osteochondro progenitor cells in the periosteum. Biochem Biophys Res Commun 2009, 386:477-482.
77. Cheah K.S., Levy A., Trainor P.A., Wai A.W., Kuffner T., So C.L., et al. Human COL2A1-directed SV40 T antigen expression in transgenic and chimeric mice results in abnormal skeletal development. J Cell Biol 1995, 128:223-237.
78. Colnot C., Lu C., Hu D., Helms J.A. Distinguishing the contributions of the perichondrium, cartilage, and vascular endothelium to skeletal development. Dev Biol 2004, 269:55-69.
79. Gebhard S., Poschl E., Riemer S., Bauer E., Hattori T., Eberspaecher H., et al. A highly conserved enhancer in mammalian type X collagen genes drives high levels of tissue-specific expression in hypertrophic cartilage in vitro and in vivo. Matrix Biol 2004, 23:309-322.
80. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.-M., Behringer R., et al. The novel zinc-finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
81. Ducy P., Karsenty G. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol Cell Biol 1995, 15:1858-1869.
82. Rossert J., Eberspaecher H., de Crombrugghe B. Separate cis-acting DNA elements of the mouse Pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J Cell Biol 1995, 129:1421-1432.
83. Kalajzic Z., Liu P., Kalajzic I., Du Z., Braut A., Mina M., et al. Directing the expression of a green fluorescent protein transgene in differentiated osteoblasts: comparison between rat type I collagen and rat osteocalcin promoters. Bone 2002, 31:654-660.
84. Kalajzic I., Kalajzic Z., Kaliterna M., Gronowicz G., Clark S.H., Lichtler A.C., et al. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J Bone Miner Res 2002, 17:15-25.
85. Boban I., Jacquin C., Prior K., Barisic-Dujmovic T., Maye P., Clark S.H., et al. The 3.6 kb DNA fragment from the rat Col1a1 gene promoter drives the expression of genes in both osteoblast and osteoclast lineage cells. Bone 2006, 39:1302-1312.
86. Hauschka P.V., Lian J.B., Cole D.E., Gundberg C.M. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 1989, 69:990-1047.
87. Frenkel B., Capparelli C., Van Auken M., Baran D., Bryan J., Stein J.L., et al. Activity of the osteocalcin promoter in skeletal sites of transgenic mice and during osteoblast differentiation in bone marrow-derived stromal cell cultures: effects of age and sex. Endocrinology 1997, 138:2109-2116.
88. Quarles L.D., Siddhanti S.R., Medda S. Developmental regulation of osteocalcin expression in MC3T3-E1 osteoblasts: minimal role of the proximal E-box cis-acting promoter elements. J Cell Biochem 1997, 65:11-24.
89. Feng J.Q., Huang H., Lu Y., Ye L., Xie Y., Tsutsui T.W., et al. The Dentin matrix protein 1 (Dmp1) is specifically expressed in mineralized, but not soft, tissues during development. J Dent Res 2003, 82:776-780.
90. George A., Sabsay B., Simonian P.A., Veis A. Characterization of a novel dentin matrix acidic phosphoprotein. Implications for induction of biomineralization. J Biol Chem 1993, 268:12624-12630.
91. Kalajzic I., Braut A., Guo D., Jiang X., Kronenberg M.S., Mina M., et al. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone 2004, 35:74-82.
92. Yang W., Lu Y., Kalajzic I., Guo D., Harris M.A., Gluhak-Heinrich J., et al. Dentin matrix protein 1 gene cis-regulation: use in osteocytes to characterize local responses to mechanical loading in vitro and in vivo. J Biol Chem 2005, 280:20680-20690.
93. Woo S.M., Rosser J., Dusevich V., Kalajzic I., Bonewald L.F. Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res 2011, [Electronic publication ahead of print].
94. Takahashi S., Goldring S., Katz M., Hilsenbeck S., Williams R., Roodman G.D. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 1995, 95:167-171.
95. Hayman A.R., Bune A.J., Cox T.M. Widespread expression of tartrate-resistant acid phosphatase (Acp 5) in the mouse embryo. J Anat 2000, 196(Pt 3):433-441.
96. Beedles K.E., Sharpe P.T., Wagner E.F., Grigoriadis A.E. A putative role for c-Fos in the pathophysiology of Paget's disease. J Bone Miner Res 1999, 14:21-28.
97. Schwartzberg P.L., Xing L., Hoffmann O., Lowell C.A., Garrett L., Boyce B.F., et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev 1997, 11:2835-2844.
98. Boyce B.F., Wright K., Reddy S.V., Koop B.A., Story B., Devlin R., et al. Targeting simian virus 40T antigen to the osteoclast in transgenic mice causes osteoclast tumors and transformation and apoptosis of osteoclasts. Endocrinology 1995, 136:5751-5759.
99. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996, 271:12511-12516.
100. Rantakokko J., Aro H.T., Savontaus M., Vuorio E. Mouse cathepsin K: cDNA cloning and predominant expression of the gene in osteoclasts, and in some hypertrophying chondrocytes during mouse development. FEBS Lett 1996, 393:307-313.
101. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA 1998, 95:13453-13458.
102. Rosmarin A.G., Weil S.C., Rosner G.L., Griffin J.D., Arnaout M.A., Tenen D.G. Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation. Blood 1989, 73:131-136.
103. Fujikawa Y., Sabokbar A., Neale S., Athanasou N.A. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996, 55:816-822.
104. Shalhoub V., Elliott G., Chiu L., Manoukian R., Kelley M., Hawkins N., et al. Characterization of osteoclast precursors in human blood. Br J Haematol 2000, 111:501-512.
105. Haegel H., Larue L., Ohsugi M., Fedorov L., Herrenknecht K., Kemler R. Lack of beta-catenin affects mouse development at gastrulation. Development 1995, 121:3529-3537.
106. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005, 8:727-738.
107. Akiyama H., Lyons J.P., Mori-Akiyama Y., Yang X., Zhang R., Zhang Z., et al. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev 2004, 18:1072-1087.